Kala Pharmaceuticals Stock Price - KALA

0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Kala Pharmaceuticals Inc KALA NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.51 -8.7% 5.35 5.18 5.98 5.57 5.86 20:00:00
Bid Price Ask Price Spread Spread % News
3.45 5.60 2.15 38.39% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
3,733 654,891 $ 5.47 $ 3,582,160 751,156 3.24 - 8.98
Last Trade Time Type Quantity Stock Price Currency
17:03:19 2 $ 5.35 USD

Kala Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 196.90M 36.80M $ -66.74M -2.76 - 36.30M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Kala Pharmaceuticals News

Loading Messages....

Latest KALA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical KALA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week6.526.605.186.15855,716-1.17-17.94%
1 Month6.167.45245.186.35644,220-0.81-13.15%
3 Months3.997.703.605.47776,1751.3634.09%
6 Months3.557.703.245.01489,1301.8050.7%
1 Year8.418.983.245.38358,734-3.06-36.39%
3 Years16.7026.753.249.69294,864-11.35-67.96%
5 Years16.7026.753.249.69294,864-11.35-67.96%

Kala Pharmaceuticals Description

Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-sized nanoparticles and have proprietary coatings. It has applied the AMPPLIFY technology to create nanosuspensions of loteprednol etabonate, or LE, acorticosteroid designed for ocular applications, resulting in two product candidates. INVELTYS was approved in August 2018 for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25 per cent is in Phase 3 development for the temporary relief of the signs and symptoms of dry eye disease.

Your Recent History
Kala Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.